217 related articles for article (PubMed ID: 17442942)
1. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy.
Kretz-Rommel A; Qin F; Dakappagari N; Ravey EP; McWhirter J; Oltean D; Frederickson S; Maruyama T; Wild MA; Nolan MJ; Wu D; Springhorn J; Bowdish KS
J Immunol; 2007 May; 178(9):5595-605. PubMed ID: 17442942
[TBL] [Abstract][Full Text] [Related]
2. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy.
Kretz-Rommel A; Qin F; Dakappagari N; Cofiell R; Faas SJ; Bowdish KS
J Immunol; 2008 Jan; 180(2):699-705. PubMed ID: 18178807
[TBL] [Abstract][Full Text] [Related]
3. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.
McWhirter JR; Kretz-Rommel A; Saven A; Maruyama T; Potter KN; Mockridge CI; Ravey EP; Qin F; Bowdish KS
Proc Natl Acad Sci U S A; 2006 Jan; 103(4):1041-6. PubMed ID: 16418292
[TBL] [Abstract][Full Text] [Related]
4. Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
Rastogi N; Baker S; Man S; Uger RA; Wong M; Coles SJ; Hodges M; Gilkes AF; Knapper S; Darley RL; Tonks A
Br J Haematol; 2021 Apr; 193(1):155-159. PubMed ID: 32996123
[TBL] [Abstract][Full Text] [Related]
5. Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.
Xiong Z; Ampudia-Mesias E; Shaver R; Horbinski CM; Moertel CL; Olin MR
Immunotherapy; 2016 Sep; 8(9):1059-71. PubMed ID: 27485078
[TBL] [Abstract][Full Text] [Related]
6. The role of CD200 in immunity to B cell lymphoma.
Wong KK; Khatri I; Shaha S; Spaner DE; Gorczynski RM
J Leukoc Biol; 2010 Aug; 88(2):361-72. PubMed ID: 20442224
[TBL] [Abstract][Full Text] [Related]
7. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200.
Siva A; Xin H; Qin F; Oltean D; Bowdish KS; Kretz-Rommel A
Cancer Immunol Immunother; 2008 Jul; 57(7):987-96. PubMed ID: 18060403
[TBL] [Abstract][Full Text] [Related]
8. Cell-surface CD200 may predict efficacy of paternal mononuclear leukocyte immunotherapy in treatment of human recurrent pregnancy loss.
Clark DA
Am J Reprod Immunol; 2009 Jan; 61(1):75-84. PubMed ID: 19086995
[TBL] [Abstract][Full Text] [Related]
9. Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression.
Kretz-Rommel A; Bowdish KS
Expert Opin Biol Ther; 2008 Jan; 8(1):5-15. PubMed ID: 18081533
[TBL] [Abstract][Full Text] [Related]
10. CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.
Liu JQ; Hu A; Zhu J; Yu J; Talebian F; Bai XF
Adv Exp Med Biol; 2020; 1223():155-165. PubMed ID: 32030689
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
12. Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model.
Curry A; Khatri I; Kos O; Zhu F; Gorczynski R
PLoS One; 2017; 12(2):e0171586. PubMed ID: 28234914
[TBL] [Abstract][Full Text] [Related]
13. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor.
Rygiel TP; Karnam G; Goverse G; van der Marel AP; Greuter MJ; van Schaarenburg RA; Visser WF; Brenkman AB; Molenaar R; Hoek RM; Mebius RE; Meyaard L
Oncogene; 2012 Jun; 31(24):2979-88. PubMed ID: 22020332
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice.
Gorczynski RM; Chen Z; Diao J; Khatri I; Wong K; Yu K; Behnke J
Breast Cancer Res Treat; 2010 Sep; 123(2):405-15. PubMed ID: 19953316
[TBL] [Abstract][Full Text] [Related]
15. Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6.
Podnos A; Clark DA; Erin N; Yu K; Gorczynski RM
Breast Cancer Res Treat; 2012 Nov; 136(1):117-27. PubMed ID: 23053647
[TBL] [Abstract][Full Text] [Related]
16. The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies.
Pilch Z; Tonecka K; Skorzynski M; Sas Z; Braniewska A; Kryczka T; Boon L; Golab J; Meyaard L; Rygiel TP
PLoS One; 2019; 14(1):e0210796. PubMed ID: 30653571
[TBL] [Abstract][Full Text] [Related]
17. Loss of surface CD200 on stored allogeneic leukocytes may impair anti-abortive effect in vivo.
Clark DA; Chaouat G
Am J Reprod Immunol; 2005 Jan; 53(1):13-20. PubMed ID: 15667521
[TBL] [Abstract][Full Text] [Related]
18. Use of an anti-CD200 antibody for prolonging the survival of allografts: a patent evaluation of WO2012106634A1.
Rygiel TP; Luijk B; Meyaard L
Expert Opin Ther Pat; 2013 Mar; 23(3):389-92. PubMed ID: 23351009
[TBL] [Abstract][Full Text] [Related]
19. CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance.
D'Arena G; De Feo V; Pietrantuono G; Seneca E; Mansueto G; Villani O; La Rocca F; D'Auria F; Statuto T; Valvano L; Arruga F; Deaglio S; Efremov DG; Sgambato A; Laurenti L
Front Oncol; 2020; 10():584427. PubMed ID: 33324560
[TBL] [Abstract][Full Text] [Related]
20. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M
Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
